FDA Approved Indications for this Orphan Drug:

Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.

FDA Marketing Approval issued as of:
02/02/1999

Orphan Drug exclusivity ends on:
02/02/2006
Company Making and Marketing this drug:
Eisai, Inc

FDA Designation Date:
3/24/98

FDA Drug Designation:
Treatment of AIDS-related Kaposi's sarcoma.